Allergic Bronchopulmonary Aspergillosis Therapeutics Market
Number of pages: 100 | Report Format: PDF | Published date: January 17, 2023
Historical Years – 2020 | Base Year – 2021 | Forecasted Years – 2022-2030
|
Report Attribute |
Details |
|
CAGR |
5.3% |
|
Base Year for Estimation |
2021 |
|
Forecast Period |
2022-2030 |
|
Historical Year |
2020 |
|
Segments Covered |
Drug Class, Route of Administration, and Region |
|
Regional Scope |
North America, Europe, Asia Pacific, and the Rest of the World (RoW) |
According to the deep-dive market assessment study by Growth Plus Reports, the global allergic bronchopulmonary aspergillosis therapeutics market is expected to register a revenue CAGR of 5.3% from 2022 to 2030.
Allergic Bronchopulmonary Aspergillosis Therapeutics Market Fundamentals
Aspergillus refers to a form of fungus frequently observed in the environment, including in the dirt, water, dust, and decaying or rotting vegetation. Aspergillosis is commonly caused by a mold called Aspergillus fumigatus. Dead leaves, compost piles, decomposing vegetable matter, stored grains, foods, and spices are frequent places where Aspergillus mold can be discovered. Mold spores can develop on carpeting, inside shoes, and on clothing. Mold growth can occur in window unit air conditioners if filters are not well-maintained and water does not drain from the unit effectively. Mold spores may be present at construction sites where buildings are being taken down or restored.
Individuals with strong immune systems do not experience any negative effects due to Aspergillus exposure. On the other hand, people with weak immune systems or chronic lung conditions are at higher risk of contracting the infection. Patients going through chemotherapy or receivers of organ transplants mostly have a compromised immune system and are at higher risk of infection. Different types of Aspergillus infections include pulmonary aspergillosis, invasive aspergillosis, and allergic bronchopulmonary aspergillosis (ABPA).
ABPA is an allergic reaction that occurs during fungus aspergillus molds (conidia) infections. Inflammation occurring due to the fungus affects the airways and lungs. Patients with cystic fibrosis, bronchiectasis, and/or asthma are more likely to experience ABPA due to the presence of more mucus in their airways, which may create an ideal habitat for the mold to develop. However, the exact causes of these allergic reactions, such as wheezing, coughing, and breathing difficulties, including asthma, are unknown.
The signs and symptoms of ABPA resemble those of lung tuberculosis and include uncontrolled hemoptysis, expectoration of mucus plugs, discomfort, and fever. Clinically, there are five stages of allergic bronchial pulmonary aspergillosis. ABPA is diagnosed with an IgE blood test, which counts the number of IgE antibodies specific to the allergen and can identify Aspergillus fumigatus allergies. Moreover, the disorder can also be diagnosed using various techniques, such as chest x-ray, skin prick test with aspergillus antigen, positive sputum culture for aspergillus, and increased level of blood eosinophils count.
Since there is now no definitive treatment solution available for ABPA, it is managed using steroids and anti-fungals to prevent lung damage. The current oral dose regimens for these drugs can last up to 6 months of therapy or more. In the treatment of ABPA, oral steroids and anti-fungal drugs are utilized to treat the infection and reduce inflammation. Oral azoles, the first-line anti-fungal treatment, are administered to about 80% of ABPA patients. Itraconazole stops the development of cell walls to inhibit fungal growth. Itraconazole specifically blocks ergosterol synthesis, which results in toxic sterols that limit the growth and reproduction of fungal cell walls.
Allergic Bronchopulmonary Aspergillosis Therapeutics Market Dynamics
The rising prevalence of respiratory diseases, such as asthma, chronic obstructive pulmonary disease (COPD), pulmonary fibrosis, and pneumonia, is driving the global allergic bronchopulmonary aspergillosis therapeutics market revenue growth. According to the National Center for Biotechnology Information, approximately 4 million people globally are affected by ABPA.
A robust product pipeline for ABPA is a significant factor boosting the global allergic bronchopulmonary aspergillosis therapeutics market revenue growth. Major players in the market are focusing on the development and launch of novel drugs for effectual treatment of aspergillosis. Hence, they are investing heavily in R&D activities. These factors are likely to help in the rapid growth of the global market during the forecast period.
Leading players are adopting key strategies, such as collaboration and acquisition. Such initiatives are helping companies in the development of new drugs, which in turn, is propelling the revenue growth of the allergic bronchopulmonary aspergillosis therapeutics market. Similarly, rising awareness about available treatment solutions for ABPA is leading to significant revenue growth in the global allergic bronchopulmonary aspergillosis therapeutics market.
However, stringent regulations associated with the drugs approval and increase in the availability of generic products are likely to restrict the revenue growth of the allergic bronchopulmonary aspergillosis therapeutics market during the forecast period. Moreover, complications related to corticosteroids, such as fluid retention, causing swelling in the lower legs, high blood pressure, and increasing drug resistance to anti-fungal drugs, are some factors hampering the revenue growth of the allergic bronchopulmonary aspergillosis therapeutics market.
Allergic Bronchopulmonary Aspergillosis Therapeutics Market Ecosystem
The global allergic bronchopulmonary aspergillosis therapeutics market is analyzed based on three parameters: drug class, route of administration, and region.
Allergic Bronchopulmonary Aspergillosis Therapeutics Market by Drug Class
[321321324]
Based on the drug class, the global allergic bronchopulmonary aspergillosis therapeutics market is segmented into azoles, antibiotics, and corticosteroids.
The corticosteroids segment dominates the global allergic bronchopulmonary aspergillosis therapeutics market with the largest revenue share. This can be attributed to increase in the usage of corticosteroids as the primary treatment solution for ABPA. Additionally, steroids assist in symptom relief, reduction of airflow obstruction, serum IgE, and peripheral blood eosinophil. These factors are driving the demand for corticosteroids. Moreover, this drug class stops permanent lung damage and helps in the treatment of pulmonary inflammation and infiltrates. Corticosteroids are the first-line treatment for ABPA in both cystic fibrosis and asthma. These factors are expected to lead to revenue growth of the segment at a rapid pace.
Allergic Bronchopulmonary Aspergillosis Therapeutics Market by Route of Administration
Based on the route of administration, the global allergic bronchopulmonary aspergillosis therapeutics market is segmented into oral, parenteral, inhalation, and others.
The oral drugs segment accounts for the largest revenue share of the global market. This is attributed to the ease of administration and improved bioavailability. The first course of treatment is oral prednisone, itraconazole, and voriconazole to lower fungal load, reduce inflammatory activity, and function as steroid-sparing agents, which are advised after the usage of corticosteroids. ABPA patients who are steroid-dependent experience recurrent relapses, and where the advantages of the treatment outweigh the dangers, are typically advised the oral usage of itraconazole.
Allergic Bronchopulmonary Aspergillosis Therapeutics Market by Region
Based on the region, the global allergic bronchopulmonary aspergillosis therapeutics market is segmented into North America, Europe, Asia Pacific, and the Rest of the World (RoW).
North America accounts for the largest revenue share of the global allergic bronchopulmonary aspergillosis therapeutics market. This can be attributed to rising prevalence of respiratory diseases, such as cystic fibrosis and asthma. Moreover, the presence of well-developed healthcare infrastructure and key companies is boosting revenue growth in the regional market. Similarly, well-established biotech and pharma companies, government initiatives to spread awareness about available treatment for aspergillosis, and increase in R&D activities are propelling the North America allergic bronchopulmonary aspergillosis therapeutics market revenue growth.
Allergic Bronchopulmonary Aspergillosis Therapeutics Market Competitive Landscape
The prominent players operating in the global allergic bronchopulmonary aspergillosis therapeutics market are:
Allergic Bronchopulmonary Aspergillosis Therapeutics Market Strategic Developments
The rising prevalence of respiratory disorders, strong product pipeline, and increased investments in R&D activities are driving the global market revenue growth.
Stringent approval process, generic competition, and rise in drug resistance to anti-fungal drugs are restricting revenue growth in the global market.
Johnson & Johnson, Pfizer Inc., Merck & Co. Inc., Astellas Pharma US Inc., and Gilead Sciences Inc. are among the prominent players operating in the global market.
*Insights on financial performance are subject to the availability of information in the public domain